This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement."
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report.
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.
